Drug profile

The FDA adverse-event record for Borrelia Burgdorferi Bacterin-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract

507 FDA reports name Borrelia Burgdorferi Bacterin-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract, a high-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#302 of 2,679
by report volume (all drugs)
507
adverse-event reports
3.9%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Borrelia Burgdorferi Bacterin-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract ranks #302 of 2679 by total reports (507) and #850 of 1130 by death-coded share (3.9%). National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#302
This drug, reports of 2679
#850
This drug, death share of 1130

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Borrelia Burgdorferi Bacterin-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract has 507 reports now versus 478 in that prior snapshot: 29 more (6.1%).

Report change
+29
Death-coded reports
+0
Death-coded share
−0.2 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Borrelia Burgdorferi Bacterin-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract changes

Signature read: 507 reports place Borrelia Burgdorferi Bacterin-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract in the upper third of FDA AER volume (#302 of 2,679).

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
507
Total Reports
20
Deaths Reported
3.9%
Death-coded share of reports

Active Ingredients

Borrelia Burgdorferi Bacterin-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract

Administration Routes

SubcutaneousParenteralUnknownOtherOralAuricular (Otic)

Species Affected

Dog 507

Most Affected Breeds

Retriever - Labrador 83
Retriever - Golden 52
Shepherd Dog - German 27
Crossbred Canine/dog 27
Shepherd Dog - Australian 23
Siberian Husky 15
Poodle (unspecified) 13
Shih Tzu 12
Mountain Dog - Bernese 10
Boxer (German Boxer) 9

Most Reported Reactions

Lack of efficacy (bacteria) - Borrelia 277
Other abnormal test result NOS 106
Lack of efficacy (ectoparasite) - tick NOS 83
Vomiting 50
Diarrhoea 36
Lethargy (see also Central nervous system depression in Neurological) 36
Lack of efficacy (bacteria) - Anaplasma 28
Partial lack of efficacy 26
Lethargy (see also Central nervous system depression in 'Neurological') 23
Proteinuria 21
Lameness 20
Behavioural disorder NOS 18

Outcome Breakdown

Outcome Unknown
363 (71.6%)
Ongoing
63 (12.4%)
Recovered/Normal
61 (12.0%)
Euthanized
13 (2.6%)
Died
7 (1.4%)

Borrelia Burgdorferi Bacterin-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract: low death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

High-volume nationwide drug peers

Two openFDA-derived peer sets for Borrelia Burgdorferi Bacterin-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract, both floored at ≥50 reports so the neighborhoods stay in the advertised mass.

Similar report volume

Nearest other drugs by FDA report count (507 here).

Rabies In Hhh Adj Pfizer Kv 508 Bordetella 511 Leptospirosis Vaccine 503 Tylosin Tartrate 513

What to do with this drug

  • Compare Borrelia Burgdorferi Bacterin-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract's report volume and death-coded share against similar drugs nationwide. See similar drugs
  • Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
  • Browse the full drug directory to compare report counts across products. All drugs

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Borrelia Burgdorferi Bacterin-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract (#302 of 2,679 by report volume); death-coded 3.9%. PlainBreed drug row · report volume stamp 507 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →